Comparative Pharmacology
Head-to-head clinical analysis: TIMOLOL MALEATE versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMOLOL MALEATE versus TRASICOR.
TIMOLOL MALEATE vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and cardiac output. Also decreases aqueous humor production in the eye by blocking beta2 receptors on ciliary epithelium.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Systemic: 1 drop of 0.25% or 0.5% solution in affected eye(s) twice daily. Additional indication: 0.5% gel-forming solution once daily. Oral: 10 mg twice daily, may increase to 20 mg twice daily if needed.
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
2-3 hours (terminal); prolonged in hepatic impairment
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Renal: 20% unchanged; biliary/fecal: 80% as metabolites
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category A/B
Category C
Beta-Blocker
Beta-Blocker